pharma · MAC Lung Disease · Mycobacterium Abscessus Infection · ANTX
AN2 Therapeutics
AN2 Therapeutics is a pharma organization headquartered in Menlo Park, USA. It trades on NYSE under ticker ANTX. Primary therapeutic focus areas include MAC Lung Disease, Mycobacterium Abscessus Infection, Renal Insuffic
Menlo Park, USA HQ
2019 Founded
35 Employees
Public company Type
ANTX · NYSE Ticker
Company details
- Status
- Public
- HQ
- Menlo Park, USA
- Founded
- 2019
- Employees
- 35
- Programs
- 6
- Drugs
- 2
- Patents
- 0
Epetraborole
Phase 3 · small molecule · MAC Lung Disease
Epetraborole for MAC Lung Disease is a Phase 3 program (small_molecule) at AN2 Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code EBO-301
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- AN2 Therapeutics
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- MAC Lung Disease
- Status
- terminated
- Trials
- 1